专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140290220A1 ENGINE UNIT 有权
标题翻译：发动机单元
公开(公告)号：US20140290220A1
公开(公告)日：2014-10-02
申请号：US14112395
申请日：2013-03-29
申请人： Taira Ozaki , Hiroshi Nakagami , Hironori Yamamitsu , Kanji Namimatsu , Hiroshi Ohta , Kenji Matsubara
发明人： Taira Ozaki , Hiroshi Nakagami , Hironori Yamamitsu , Kanji Namimatsu , Hiroshi Ohta , Kenji Matsubara
IPC分类号： F01N3/08
CPC分类号： F01N3/08 , F01N3/021 , F01N3/10 , F01N13/009 , F01N13/1816 , F01N13/1822 , F01N2470/12 , F01N2590/08 , Y02T10/20
摘要： An engine unit includes an engine, an exhaust gas treatment device and a connecting pipe. The engine has an exhaust gas port. The exhaust gas treatment device is arranged above the engine. The connecting pipe connects the exhaust gas port and the exhaust gas treatment device. The connecting pipe has an expandable-contractible bellows portion. The bellows portion has a linear form following the upward-downward direction. The lower end portion of the bellows portion is positioned lower than at least a part of the exhaust gas port.
摘要翻译：发动机单元包括发动机，废气处理装置和连接管。发动机有排气口。排气处理装置设置在发动机的上方。连接管连接排气口和废气处理装置。连接管具有可膨胀收缩的波纹管部分。波纹管部分沿着向上 - 向下的方向具有线性形式。波纹管部的下端部位于排气口的至少一部分的下方。

2. 发明申请

US20140228377A1 METHYLPIPERIDINE DERIVATIVE 审中-公开
标题翻译：甲基哌啶衍生物
公开(公告)号：US20140228377A1
公开(公告)日：2014-08-14
申请号：US14131090
申请日：2012-07-04
申请人： Masahito Abe , Aya Futamura , Ryo Suzuki , Dai Nozawa , Hiroshi Ohta , Yuko Araki
发明人： Masahito Abe , Aya Futamura , Ryo Suzuki , Dai Nozawa , Hiroshi Ohta , Yuko Araki
IPC分类号： C07D498/04 , C07D413/14
CPC分类号： C07D498/04 , C07D413/14
摘要： A compound represented by formula (IA) or a pharmaceutically acceptable salt thereof, which acts relying on an orexin (OX) receptor antagonistic activity and is useful for the treatment or prevention of diseases such as sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependence, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, head ache, migraine, pain, gastrointestinal diseases, epilepsy, inflammations, immune-related diseases, endocrine-related diseases and hypertension.
摘要翻译：由式（IA）表示的化合物或其药学上可接受的盐，其依赖于食欲肽（OX）受体拮抗活性，并且可用于治疗或预防诸如睡眠障碍，抑郁症，焦虑障碍，恐慌症，精神分裂症，药物依赖，阿尔茨海默病，帕金森病，亨廷顿舞蹈病，饮食失调，头痛，偏头痛，疼痛，胃肠道疾病，癫痫，炎症，免疫相关疾病，内分泌相关疾病和高血压。

3. 发明申请

US20140081025A1 HETEROAROMATIC RING DERIVATIVE 审中-公开
标题翻译：异位环衍生物
公开(公告)号：US20140081025A1
公开(公告)日：2014-03-20
申请号：US14115933
申请日：2012-05-08
申请人： Ryo Suzuki , Aya Futamura , Masahito Abe , Shuhei Kashiwa , Nobutaka Hattori , Dai Nozawa , Hiroshi Ohta , Yuko Araki
发明人： Ryo Suzuki , Aya Futamura , Masahito Abe , Shuhei Kashiwa , Nobutaka Hattori , Dai Nozawa , Hiroshi Ohta , Yuko Araki
IPC分类号： C07D413/14 , C07D413/12 , C07D401/14
CPC分类号： C07D413/14 , C07D401/14 , C07D403/12 , C07D413/12
摘要： The compound represented by formula (IA) or a pharmaceutically acceptable salt thereof is based on orexin (OX) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.
摘要翻译：由式（IA）表示的化合物或其药学上可接受的盐是基于食欲肽（OX）受体拮抗剂活性，可用于治疗和预防包括睡眠障碍，抑郁症，焦虑障碍，恐慌症，精神分裂症，药物依赖性，阿尔茨海默病，帕金森病，亨廷顿舞蹈病，进食障碍，疼痛，胃肠道疾病，癫痫，炎症，免疫疾病，内分泌相关疾病和高血压。

4. 发明授权

US08643056B2 Power semiconductor device and method of manufacturing the same 失效
标题翻译：功率半导体器件及其制造方法
公开(公告)号：US08643056B2
公开(公告)日：2014-02-04
申请号：US13229203
申请日：2011-09-09
申请人： Kiyoshi Kimura , Yasuto Sumi , Hiroshi Ohta , Hiroyuki Irifune
发明人： Kiyoshi Kimura , Yasuto Sumi , Hiroshi Ohta , Hiroyuki Irifune
IPC分类号： H01L29/66
CPC分类号： H01L29/0634 , H01L29/0638 , H01L29/0696 , H01L29/0878 , H01L29/1095 , H01L29/402 , H01L29/66712 , H01L29/7395 , H01L29/7802 , H01L29/7811 , H01L29/872
摘要： A power semiconductor device includes a first semiconductor layer of a first conductivity type, a first drift layer, and a second drift layer. The first drift layer includes a first epitaxial layer of the first conductivity type, a plurality of first first-conductivity-type pillar layers, and a plurality of first second-conductivity-type pillar layers. The second drift layer is formed on the first drift layer and includes a second epitaxial layer of the first conductivity type, a plurality of second second-conductivity-type pillar layers, a plurality of second first-conductivity-type pillar layers, a plurality of third second-conductivity-type pillar layers, and a plurality of third first-conductivity-type pillar layers. The plurality of second second-conductivity-type pillar layers are connected to the first second-conductivity-type pillar layers. The plurality of second first-conductivity-type pillar layers are connected to the first first-conductivity-type pillar layers. The plurality of third second-conductivity-type pillar layers are arranged on the first epitaxial layer.
摘要翻译：功率半导体器件包括第一导电类型的第一半导体层，第一漂移层和第二漂移层。第一漂移层包括第一导电类型的第一外延层，多个第一第一导电型柱层和多个第一第二导电型柱层。第二漂移层形成在第一漂移层上，并且包括第一导电类型的第二外延层，多个第二第二导电型柱层，多个第二第一导电型柱层，多个第二导电型柱层第三第二导电型柱层和多个第三第一导电型柱层。多个第二第二导电型柱层与第一第二导电型柱层连接。多个第二第一导电型柱层与第一第一导电型柱层连接。多个第三第二导电型柱层布置在第一外延层上。

5. 发明申请

US20130331571A1 GLYCINE TRANSPORTER-INHIBITING SUBSTANCES 有权
标题翻译：甘氨酸运输抑制物质
公开(公告)号：US20130331571A1
公开(公告)日：2013-12-12
申请号：US14000261
申请日：2012-02-21
申请人： Minoru Moriya , Hiroshi Ohta , Shuji Yamamoto , Kumi Abe , Yuko Araki , Xiang-Min Sun , Daisuke Wakasugi
发明人： Minoru Moriya , Hiroshi Ohta , Shuji Yamamoto , Kumi Abe , Yuko Araki , Xiang-Min Sun , Daisuke Wakasugi
IPC分类号： C07D401/04 , C07D417/14 , C07D413/14 , C07D401/14
CPC分类号： C07D401/04 , C07D401/14 , C07D413/14 , C07D417/14
摘要： The present invention relates to novel compounds of formula [I] or pharmaceutically acceptable salts thereof: The compounds of the present invention are useful in the prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, spasm, tremor, pain, Parkinson's disease, attention deficit hyperactivity disorder, bipolar disorder, eating disorder, or sleep disorders, which is based on the glycine uptake-inhibiting action.
摘要翻译：本发明涉及式[I]的新化合物或其药学上可接受的盐：本发明的化合物可用于预防或治疗诸如精神分裂症，阿尔茨海默氏病，认知障碍，痴呆，焦虑症（例如，广泛性焦虑症，恐慌症，强迫症，社交焦虑症，创伤后应激障碍，特异性恐惧症，急性应激障碍），抑郁症，药物依赖性，痉挛，震颤，疼痛，帕金森病，注意缺陷多动障碍，双相紊乱，进食障碍或睡眠障碍，其基于甘氨酸摄取抑制作用。

6. 发明申请

US20130142948A1 PHOTOCHROMIC LENS MANUFACTURING SYSTEM, PHOTOCHROMIC LENS MANUFACTURING DEVICE, PHOTOCHROMIC LENS MANUFACTURING PROGRAM, RECORDING MEDIUM HAVING PHOTOCHROMIC LENS MANUFACTURING PROGRAM RECORDED THEREUPON, AND PHOTOCHROMIC LENS MANUFACTURING METHOD 审中-公开
标题翻译：光致变色镜制造系统，光致变色镜制造装置，光致变色镜制造程序，具有记录的光致变色镜制造程序的记录介质和光致变色镜制造方法
公开(公告)号：US20130142948A1
公开(公告)日：2013-06-06
申请号：US13258853
申请日：2010-03-31
申请人： Hiroshi Ohta , Takeshi Imizu , Takamitsu Hirose , Toshikazu Hashimoto
发明人： Hiroshi Ohta , Takeshi Imizu , Takamitsu Hirose , Toshikazu Hashimoto
IPC分类号： B05D5/06 , G05B15/00
CPC分类号： B05D5/066 , G02B5/23 , G02C7/102 , G05B15/00
摘要： A photochromic lens manufacturing system has an orderer side computer (101) and a manufacturer side computer (201) connected with each other through a communication line (300), and is adapted to manufacture a photochromic lens with an optical surface forming device (204), a photochromic film forming device (202) and a hard film forming device (204) under control of the manufacturer side computer (201). The orderer side computer (101) transmits lens substrate data related to a substrate material of the lens, optical surface data related to optical surfaces of the lens, data related to the photochromic film and data related to a hard film to the manufacturer side computer (201) through the communication line (300).The manufacturer side computer (201) comprises: a lens substrate selecting means adapted to select a lens substrate formed of a suitable material based on the lens substrate data received from the orderer side computer; an optical surface forming data selecting means adapted to select suitable optical surface forming data based on the optical surface data and output the selected data to the optical surface forming device (202); a photochromic film forming data selecting means adapted to select forming data of the photochromic film based on the data related to the photochromic film, and output the selected data to the photochromic film forming device (203); and a hard film forming data selecting means adapted to select forming data of the hard film based on the data related to the hard film, and output the selected data to the hard film forming device (204).
摘要翻译：光致变色透镜制造系统具有通过通信线路（300）彼此连接的订制器侧计算机（101）和制造商侧计算机（201），并且适于制造具有光学表面形成装置（204）的光致变色透镜，，光致变色膜形成装置（202）和在制造商侧计算机（201）的控制下的硬膜形成装置（204）。订书机侧计算机（101）将与透镜的基板材料相关的透镜基板数据，与透镜的光学表面相关的光学表面数据，与光致变色膜相关的数据和与硬膜相关的数据传送到制造商侧计算机 201）通过通信线路（300）。制造商侧计算机（201）包括：透镜基板选择装置，适于基于从订书机侧计算机接收的透镜基板数据来选择由合适材料形成的透镜基板; 光学表面形成数据选择装置，适于基于所述光学表面数据选择合适的光学表面形成数据并将所选择的数据输出到所述光学表面形成装置（202）; 基于与所述光致变色膜相关的数据选择所述光致变色膜的形成数据的光致变色膜形成数据选择装置，并将所选择的数据输出到所述光致变色膜形成装置（203）。以及硬膜成形数据选择装置，其适于基于与所述硬膜相关的数据来选择所述硬膜的形成数据，并将所选择的数据输出到所述硬膜形成装置（204）。

7. 发明申请

US20130123500A1 ETHINYL-PYRAZOLE DERIVATIVE 失效
标题翻译：乙烯基吡唑衍生物
公开(公告)号：US20130123500A1
公开(公告)日：2013-05-16
申请号：US13812437
申请日：2011-07-29
申请人： Toshio Nakamura , Kazunari Sakagami , Kazuhide Konishi , Kanako Yamamoto , Seiji Masuda , Yohei Matsuda , Kumiko Okada , Tsuyoshi Shibata , Hiroshi Ohta , Akito Yasuhara , Hiroshi Kawamoto
发明人： Toshio Nakamura , Kazunari Sakagami , Kazuhide Konishi , Kanako Yamamoto , Seiji Masuda , Yohei Matsuda , Kumiko Okada , Tsuyoshi Shibata , Hiroshi Ohta , Akito Yasuhara , Hiroshi Kawamoto
IPC分类号： C07D231/12 , C07D231/20 , C07D231/38 , C07D403/06 , C07D401/06
CPC分类号： C07D231/12 , C07D231/14 , C07D231/20 , C07D231/38 , C07D401/04 , C07D401/06 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/06 , C07D413/04
摘要： Provided is a novel compound represented by formula [I] or a pharmaceutically acceptable salt thereof having antagonistic activity against group II metabolism-type glutamic acid (m-Glu) receptors. The compound or pharmaceutically acceptable salt thereof is useful as a prophylactic or therapeutic agent for diseases such as new mood disorders (depressive and bipolar disorders), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, and acute stress disorder), schizophrenia, Alzheimer's disease, cognitive dysfunction, dementia, drug dependence, convulsions, tremors, pain, sleep disorders, and the like.
摘要翻译：本发明提供由式[I]表示的新化合物或其对II类代谢型谷氨酸（m-Glu）受体具有拮抗作用的药学上可接受的盐。化合物或其药学上可接受的盐可用作疾病的预防或治疗剂，例如新的情绪障碍（抑郁和双相性精神障碍），焦虑症（广泛性焦虑症，惊恐障碍，强迫症，社会焦虑症，创伤性应激障碍，特异性恐惧症和急性应激障碍），精神分裂症，阿尔茨海默病，认知功能障碍，痴呆，药物依赖，惊厥，震颤，疼痛，睡眠障碍等。

8. 发明授权

US08283720B2 Power semiconductor device 有权
标题翻译：功率半导体器件
公开(公告)号：US08283720B2
公开(公告)日：2012-10-09
申请号：US12050415
申请日：2008-03-18
申请人： Wataru Saito , Syotaro Ono , Masakatsu Takashita , Yauto Sumi , Masaru Izumisawa , Wataru Sekine , Hiroshi Ohta , Shoichiro Kurushima
发明人： Wataru Saito , Syotaro Ono , Masakatsu Takashita , Yauto Sumi , Masaru Izumisawa , Wataru Sekine , Hiroshi Ohta , Shoichiro Kurushima
IPC分类号： H01L29/00 , H01L29/66
CPC分类号： H01L29/7802 , H01L29/0634 , H01L29/0878 , H01L29/1095
摘要： A power semiconductor device includes: a first semiconductor layer; a second semiconductor layer and a third semiconductor layer provided in an upper portion of the first semiconductor layer and alternately arranged parallel to an upper surface of the first semiconductor layer; a plurality of fourth semiconductor layers provided on the third semiconductor layer; a fifth semiconductor layer selectively formed in an upper surface of each of the fourth semiconductor layers; a control electrode; a gate insulating film; a first main electrode provided on a lower surface of the first semiconductor layer; and a second main electrode provided on the fourth and the fifth semiconductor layers. Sum of the amount of impurities in the second semiconductor layer and the amount of impurities in the third semiconductor layer at an end on the second main electrode side of the second semiconductor layer and the third semiconductor layer is smaller than the sum at a center of the second semiconductor layer and the third semiconductor layer in the direction from the first main electrode to the second main electrode.
摘要翻译：功率半导体器件包括：第一半导体层; 第二半导体层和第三半导体层，设置在所述第一半导体层的上部并且交替地平行于所述第一半导体层的上表面布置; 设置在所述第三半导体层上的多个第四半导体层; 选择性地形成在每个第四半导体层的上表面中的第五半导体层; 控制电极; 栅极绝缘膜; 设置在所述第一半导体层的下表面上的第一主电极; 以及设置在第四和第五半导体层上的第二主电极。第二半导体层中的杂质量和第二半导体层的第二主电极侧端部的第三半导体层中的杂质量的和小于第二半导体层的第二主电极侧的和第二半导体层和第三半导体层在从第一主电极到第二主电极的方向上。

9. 发明申请

US20120116095A1 GLYCINE TRANSPORTER INHIBITORS 审中-公开
标题翻译：甘油运输车辆抑制剂
公开(公告)号：US20120116095A1
公开(公告)日：2012-05-10
申请号：US13383513
申请日：2010-07-15
申请人： Akito Yasuhara , Kazunari Sakagami , Hiroshi Ohta , Masato Hayashi , Yoshihisa Shirasaki , Shuji Yamamoto , Youichi Shimazaki , Yuko Araki , Kumi Abe , Xiang-Min Sun
发明人： Akito Yasuhara , Kazunari Sakagami , Hiroshi Ohta , Masato Hayashi , Yoshihisa Shirasaki , Shuji Yamamoto , Youichi Shimazaki , Yuko Araki , Kumi Abe , Xiang-Min Sun
IPC分类号： C07D249/12 , C07D233/14
CPC分类号： C07D249/10
摘要： The present invention aims to provide novel compounds represented by formula [I] or pharmaceutically acceptable salts thereof: which are useful for prevention or treatment of diseases such as schizophrenia, Alzheimer's disease, cognitive impairment, dementia, anxiety disorders (e.g., generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, post-traumatic stress disorder, specific phobias, acute stress disorder), depression, drug dependence, convulsion, tremor, pain, or sleep disorders, based on their inhibitory effect against glycine uptake.
摘要翻译：本发明旨在提供由式[I]表示的新化合物或其药学上可接受的盐：其可用于预防或治疗诸如精神分裂症，阿尔茨海默病，认知障碍，痴呆，焦虑症（例如广泛性焦虑症，基于它们对甘氨酸摄取的抑制效果，恐慌症，强迫症，社交焦虑症，创伤后应激障碍，特异性恐惧症，急性应激障碍），抑郁症，药物依赖性，惊厥，震颤，疼痛或睡眠障碍。

10. 发明授权

US08030499B2 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle 有权
标题翻译： 1,3-二氢-2H-吲哚-2-酮化合物和与芳族杂环稠合的吡咯烷-2-酮化合物
公开(公告)号：US08030499B2
公开(公告)日：2011-10-04
申请号：US11883236
申请日：2006-01-30
申请人： Yoshinori Sekiguchi , Takeshi Kuwada , Masato Hayashi , Dai Nozawa , Yuri Amada , Tsuyoshi Shibata , Shuji Yamamoto , Hiroshi Ohta , Taketoshi Okubo , Takeshi Koami
发明人： Yoshinori Sekiguchi , Takeshi Kuwada , Masato Hayashi , Dai Nozawa , Yuri Amada , Tsuyoshi Shibata , Shuji Yamamoto , Hiroshi Ohta , Taketoshi Okubo , Takeshi Koami
IPC分类号： C07D209/04 , A61K31/404
CPC分类号： C07D401/12 , C07C309/87 , C07D209/38 , C07D209/40 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/14 , C07D413/04 , C07D417/12
摘要： It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.
摘要翻译：旨在提供对精氨酸 - 加压素V1b受体有关的病理状况有效的药物。更具体地说，它旨在提供一种对抑郁，焦虑，阿尔茨海默病，帕金森病，亨廷顿氏舞蹈病，进食障碍，高血压，消化系统疾病，药物成瘾，癫痫，脑梗死，脑缺血具有治疗或预防作用的药物，脑水肿，头部损伤，炎症，免疫疾病，脱发等。作为深入研究的结果，作为精氨酸 - 加压素V1b受体的高度选择性拮抗剂的与杂芳环稠合的新的1,3-二氢-2H-吲哚-2-酮化合物和吡咯烷-2-酮化合物具有发现高代谢稳定性并显示有利的脑渗透和高血浆浓度，从而实现上述目的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式